EUVIMEDEUVIMED entdecken
Leserbrief

Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?

Wenqiang Chen, Qiuhong Ma, Zhenzhen Chen iD

American Journal of Hematology · 2026-12 · 101 (12) · 3052-3053

DOI: 10.1002/ajh.70493 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 13.09.2026. Verfasst von Wenqiang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zibo Central Hospital, Zibo, People's Republic of China. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CAR T‐cell therapyduplicate datahemophagocytic lymphohistiocytosismeta‐analysistisagenlecleucel

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Zibo Central Hospital, Zibo, People's Republic of China.
  • Department of Respiratory Medicine, Zibo Central Hospital Affiliated to Shandong Medical and Pharmaceutical University, Zibo, China.

ORCID-Profile: Zhenzhen Chen

Zitieren

APA

Chen, W., Ma, Q., & Chen, Z. (2026). Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?. American Journal of Hematology, 101(12), 3052-3053. https://doi.org/10.1002/ajh.70493

Vancouver

Chen W, Ma Q, Chen Z. Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?. American Journal of Hematology. 2026;101(12):3052-3053. doi:10.1002/ajh.70493

BibTeX
@article{Chen2026,
  author = {Chen, Wenqiang and Ma, Qiuhong and Chen, Zhenzhen},
  title = {Could Mixed CAR T‐Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {12},
  pages = {3052--3053},
  doi = {10.1002/ajh.70493}
}
Kostenlos starten →